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times higher than in those from
patients with no history of treatment.
However, the prevalence of monore-
sistant strains was low (5.3%, 4.3%,
0.3%, and 4.3% for isoniazid,
rifampicin, ethambutol, and strepto-
mycin, respectively) compared with
the prevalence of multidrug-resistant
strains whose rate reached a peak of
30.4%. 
Drug-resistant TB in countries
with good national control programs,
such as in Western Europe, is not
commonly a major health problem,
although increasing immigration
prompts public health authorities to
maintain vigilant surveillance sys-
tems. The results of our study indi-
cate that throughout Italy, prevalence
of resistance to firstline drugs and
multidrug resistance among isolates
from new cases was consistently low
over the 4-year survey period.
Prevalence of multidrug resistance
among isolates from previously treat-
ed patients was high, although a
downward trend could be demon-
strated during the last 2 years. Since
almost 2 out of 10 isolates resistant to
rifampicin were multidrug resistant,
using rapid molecular methods to
identify rifampicin resistance in ques-
tionable cases appears cost-effective
to facilitate early detection and con-
trol of multidrug-resistant TB (10).
Resistance to isoniazid is associated
with immigration from countries
where isoniazid was used extensively
in the past. This information is a use-
ful tool for clinicians, as isoniazid
resistance may be suspected early in
the disease and properly treated.
Finally, the finding of substantial
multidrug resistance among isolates
from previously treated patients,
combined with the evidence that
immigrants from areas where isoni-
azid resistance is endemic contribute
substantially to the number of new
TB cases in Italy every year, strongly
suggests that public health action is
needed to improve treatment out-
comes. 
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Mollaret-like Cells
in Patients with
West Nile Virus
Infection
To the Editor: We have read with
interest many of the articles concern-
ing West Nile virus (WNV) published
in the July 2003 issue of Emerging
Infectious Diseases. Last summer
Ohio was one of the leading states
with WNV infection in humans.
Consequently, requests for tests for
this pathogen have increased.
Unfortunately, the turnaround time
for testing these specimens may be
delayed because of shipping difficul-
ties, the limited number of laborato-
ries that can perform these assays,
and an increase in requests at testing
facilities. 
Cytologic examination of cere-
brospinal fluid (CSF) from patients
with WNV has not been studied.
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Although cytologic examination of
CSF from patients with encephalitis is
likely nonspecific, it may provide
supportive information of the suspect-
ed disease process, and is useful for
excluding other conditions, such as
neoplasia. Of the 22 patients that were
hospitalized at our institution last year
with WNV meningoencephalitis, doc-
umented by serologic tests and/or
reverse transcription-polymerase
chain reaction, CSF of 4 of these
patients was submitted for cytologic
examination. Of these 4, 3 had a suf-
ficient number of cells in the CSF
specimen (47, 213, and 495 cell/µL)
to afford cytologic examination,
whereas one had a paucicellular CSF,
with only 2 white blood cells/µL. The
cytologic features from the 3 patients,
>10 cells/µL consistently demonstrat-
ed a mixture of lymphocytes at vari-
ous stages of activation and occasion-
al large monocytic-like cells with
cerebriform nuclei reminiscent of the
Mollaret cells described in CSF of
patients with recurrent meningitis
(Figure).
Mollaret described cells with
enlarged nuclei and cerebreform
nuclear contours in CSF of patients
with recurrent, aseptic meningitis (1).
Although he believed these were of
endothelial origin, immunohisto-
chemical studies have subsequently
shown that they are monocytes (2).
This type of meningitis, now com-
monly known as Mollaret meningitis,
has been associated with herpes sim-
plex virus encephalitis, but the defini-
tive cause of all cases remains unclear
(3).
One of the patients infected with
WNV meningoencephalitis who had
Mollaret-like cells in CSF died.
Postmortem neuropathologic exami-
nation showed an extensive perivascu-
lar lymphocytic infiltrate which con-
tained mononuclear cells consistent
with the Mollaret-like cells in CSF.
These mononuclear cells were stained
with an immunohistochemical stain
directed against the CD68 antigen,
which supports a monocytic origin (4).
Further studies are needed to delineate
the consistency of Mollaret-like cells
in CSF of patients with WNV menin-
goencephalitis. Finding Mollaret-like
cells admixed with activated lympho-
cytes may be a useful, readily-avail-
able test that provides supportive evi-
dence of viral encephalitis in the
appropriate clinical setting, until more
definitive tests are available.
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Newly Isolated
Vibrio cholerae
Non-O1, Non-O139
Phages 
To the Editor: The epidemic
cholera caused by Vibrio cholerae O1
appeared in Latin America in 1991
after a 100-year absence. Following
its explosive appearance in Peru, trav-
elers on the Amazon River brought
cholera to Brazil by April 1991. It
spread southward along the Atlantic
Coast of Brazil, reaching Rio de
Janeiro in February 1993.
Phage typing is a useful tool for
studying the source or origin of V.
cholerae for epidemiologic impor-
tance. Because of limitations of the
Basu and Mukerjee scheme, a new
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Figure. Three Mollaret-like cells are present (center), with a neutrophil (upper left) and a
lymphocyte (upper right) in cerebrospinal fluid from a patient with West Nile virus
encephalitis, confirmed by reverse transcription–polymerase chain reaction and serologic
testing (Papanicolaou stain; magnification x500).